Publications
Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level
1 April 2020
The World Health Organisation (WHO) has become quite skilled at promoting what changes are desirable in health care systems, and why, but has largely left how…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…
Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?
3 January 2020
Meningococcal disease is a life-threatening infection and can result in severe sequelae. Recent scientific and technical advances have led to the discovery and implementation of novel…
The Evolution of US Policy Responses to the Opioid Epidemic
1 March 2020
The ‘opioid epidemic’ in the US is the most recent drug-abuse challenge from the misuse of prescription medicines or the use of illicit drugs. It is…
Evaluating the Cost-effectiveness of Health System Strengthening: A Platforms Perspective
1 February 2020
Health System Strengthening (HSS) is an important concept now widely discussed, but too often without sufficient structure or an adequate understanding of what actually is involved. The articles on which this seminar is based (Morton, Thomas and Smith, 2016; Smith and Yip, 2016) attempted to present more clearly just what health system strengthening might entail and whether that might be modelled.
What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment
2 January 2020
The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and…
Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
1 February 2020
Cost-Effectiveness Thresholds (CETs) are used in a selected number of countries as tool in decision-making on funding and reimbursements for new healthcare technologies.
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
1 January 2020
To date there have been no value sets to support the use of the EQ-5D-Y in cost-utility analysis. Discrete choice experiments (DCEs) can be used to…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
1 January 2020
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting…